JP2018521641A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521641A5 JP2018521641A5 JP2017563564A JP2017563564A JP2018521641A5 JP 2018521641 A5 JP2018521641 A5 JP 2018521641A5 JP 2017563564 A JP2017563564 A JP 2017563564A JP 2017563564 A JP2017563564 A JP 2017563564A JP 2018521641 A5 JP2018521641 A5 JP 2018521641A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- cancer
- cell
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021092252A JP7404306B2 (ja) | 2015-07-01 | 2021-06-01 | 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2023209805A JP2024037858A (ja) | 2015-07-01 | 2023-12-13 | 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562187507P | 2015-07-01 | 2015-07-01 | |
| US62/187,507 | 2015-07-01 | ||
| GB1511546.2 | 2015-07-01 | ||
| GBGB1511546.2A GB201511546D0 (en) | 2015-07-01 | 2015-07-01 | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| PCT/EP2016/065166 WO2017001491A2 (en) | 2015-07-01 | 2016-06-29 | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021092252A Division JP7404306B2 (ja) | 2015-07-01 | 2021-06-01 | 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018521641A JP2018521641A (ja) | 2018-08-09 |
| JP2018521641A5 true JP2018521641A5 (enExample) | 2019-06-13 |
Family
ID=53872514
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563564A Pending JP2018521641A (ja) | 2015-07-01 | 2016-06-29 | 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| JP2021092252A Active JP7404306B2 (ja) | 2015-07-01 | 2021-06-01 | 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021092252A Active JP7404306B2 (ja) | 2015-07-01 | 2021-06-01 | 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
Country Status (24)
| Country | Link |
|---|---|
| US (19) | US10738094B2 (enExample) |
| EP (2) | EP3317296B1 (enExample) |
| JP (2) | JP2018521641A (enExample) |
| KR (1) | KR20180022968A (enExample) |
| CN (1) | CN113480604A (enExample) |
| AU (2) | AU2016286274B2 (enExample) |
| BR (1) | BR112017027459A2 (enExample) |
| CA (1) | CA2990989A1 (enExample) |
| CR (1) | CR20180001A (enExample) |
| DK (1) | DK3317296T3 (enExample) |
| EA (2) | EA201992664A3 (enExample) |
| ES (1) | ES2839223T3 (enExample) |
| GB (1) | GB201511546D0 (enExample) |
| HU (1) | HUE052820T2 (enExample) |
| LT (1) | LT3317296T (enExample) |
| MA (2) | MA41520B2 (enExample) |
| MD (1) | MD3317296T2 (enExample) |
| MX (1) | MX2017017145A (enExample) |
| PT (1) | PT3317296T (enExample) |
| RS (1) | RS61190B1 (enExample) |
| SG (1) | SG10202001665QA (enExample) |
| SI (1) | SI3317296T1 (enExample) |
| UA (1) | UA123699C2 (enExample) |
| WO (1) | WO2017001491A2 (enExample) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS53350B (sr) | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze |
| HRP20140309T1 (hr) | 2008-10-22 | 2014-05-09 | Array Biopharma, Inc. | SUPSTITUIRANI SPOJEVI PIRAZOLO[1,5-a]PIRIMIDINA KAO INHIBITORI TRK KINAZE |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| KR102015402B1 (ko) | 2010-05-20 | 2019-08-28 | 어레이 바이오파마 인크. | Trk 키나제 저해제로서의 매크로시클릭 화합물 |
| JP6914834B2 (ja) | 2014-11-16 | 2021-08-04 | アレイ バイオファーマ インコーポレイテッド | （Ｓ）−Ｎ−（５−（（Ｒ）−２−（２，５−ジフルオロフェニル）−ピロリジン−１−イル）−ピラゾロ［１，５−ａ］ピリミジン−３−イル）−３−ヒドロキシピロリジン−１−カルボキサミド硫酸水素塩の結晶形 |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| EP3919507A3 (en) | 2015-07-01 | 2022-01-12 | Immatics Biotechnologies GmbH | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| US10716544B2 (en) | 2015-10-08 | 2020-07-21 | Zmk Medical Technologies Inc. | System for 3D multi-parametric ultrasound imaging |
| TN2018000138A1 (en) | 2015-10-26 | 2019-10-04 | Array Biopharma Inc | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| GB201520563D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201521746D0 (en) | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| KR102883915B1 (ko) | 2015-12-16 | 2025-11-18 | 시애틀 프로젝트 코포레이션 | 신생항원 동정, 제조, 및 용도 |
| GB201602918D0 (en) * | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| AU2017246554B2 (en) | 2016-04-04 | 2022-08-18 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| US11261223B2 (en) * | 2016-05-11 | 2022-03-01 | The University Of Chicago | Methods of treating cancers with CT45 targeted therapies |
| KR102566858B1 (ko) | 2016-05-18 | 2023-08-11 | 어레이 바이오파마 인크. | (s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법 |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| KR102590454B1 (ko) | 2016-07-07 | 2023-10-17 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| WO2018098715A1 (zh) * | 2016-11-30 | 2018-06-07 | 深圳华大基因研究院 | 多肽及其应用 |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| CN106636107B (zh) * | 2017-01-20 | 2018-07-31 | 江苏集萃药康生物科技有限公司 | 一种喉癌细胞的核酸适配体及试剂盒 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| EP3609530A1 (en) * | 2017-04-10 | 2020-02-19 | Immatics Biotechnologies GmbH | Peptides and combination thereof for use in the immunotherapy against cancers |
| KR101970709B1 (ko) | 2017-06-13 | 2019-04-22 | 가톨릭대학교 산학협력단 | ＰＬＫ１ 단백질에 대한 항원―특이 Ｔ 세포 면역반응을 유도하는 ＨＬＡ―Ａ２ 아형―특이 ＰＬＫｌ―유래 항원결정기 |
| DE102017115966A1 (de) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
| PT3428194T (pt) | 2017-07-14 | 2021-11-18 | Immatics Biotechnologies Gmbh | Molécula de polipéptido com especificidade dupla melhorada |
| WO2019025433A1 (en) * | 2017-08-02 | 2019-02-07 | Idp Discovery Pharma, S.L. | PEPTIDES WITH ANTICANCER ACTIVITY |
| CA3076918A1 (en) * | 2017-10-02 | 2019-04-11 | Curematch, Inc. | Method of prediction of tumor-derived neo-peptide antigenicity and/or immunogenicity using mutational signature patterns |
| WO2019075112A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS |
| KR20260008173A (ko) | 2017-11-22 | 2026-01-15 | 시애틀 프로젝트 코포레이션 | 신생항원에 대한 접합 에피토프 제시 감소 |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| WO2019112489A1 (en) * | 2017-12-05 | 2019-06-13 | Limited Liability Company "Gero" | Methods and agents for treatment of aging and aging related conditions and diseases |
| WO2019152741A1 (en) * | 2018-01-31 | 2019-08-08 | Nx Prenatal Inc. | Methods of early prediction and prevention of preeclampsia utilizing circulating microparticle-associated biomarkers |
| JP7470640B2 (ja) | 2018-02-09 | 2024-04-18 | イマティクス ユーエス，アイエヌシー． | Ｔ細胞を製造する方法 |
| CA3090700A1 (en) | 2018-02-12 | 2019-08-15 | Fred Hutchinson Cancer Research Center | Cyclin a1 specific t cell receptors and uses thereof |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| TW202016131A (zh) * | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | 用於抗癌免疫治療的肽 |
| CN108939090B (zh) * | 2018-07-13 | 2021-01-01 | 厦门大学 | 一种脂质体、制备方法及用途 |
| TW202019955A (zh) * | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| JP2022525594A (ja) | 2019-03-15 | 2022-05-18 | ボルト バイオセラピューティクス、インコーポレーテッド | Ｈｅｒ２を標的とする免疫結合体 |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| MA56036A (fr) | 2019-05-27 | 2022-04-06 | Immatics Us Inc | Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive |
| US20200384028A1 (en) | 2019-06-06 | 2020-12-10 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| US12569546B2 (en) | 2019-06-11 | 2026-03-10 | Iogenetics, Llc | Neoantigen immunotherapies |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| CN112409449B (zh) * | 2019-08-19 | 2023-12-15 | 辽宁中健医药科技有限公司 | Hla-a0201限定性kif15特异性抗肿瘤ctl优势表位肽及应用 |
| US12622926B2 (en) | 2019-09-02 | 2026-05-12 | Institut Curie | Immunotherapy targeting tumor neoantigenic peptides |
| CN110596386B (zh) * | 2019-09-20 | 2020-06-02 | 四川大学华西医院 | Egflam自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
| AU2021225817A1 (en) | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| EP4127243B1 (en) * | 2020-03-23 | 2023-11-22 | Koninklijke Philips N.V. | Prediction of radiotherapy response for prostate cancer subject based on immune checkpoint genes |
| IL296881A (en) * | 2020-04-14 | 2022-12-01 | Universit? De Montr?Al | New antigens specific for acute myeloid leukemia (aml) and their uses |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022011197A1 (en) * | 2020-07-08 | 2022-01-13 | Mercy Bioanalytics, Inc. | Compositions and methods for detection of lung cancer |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| CN112691192B (zh) * | 2020-12-01 | 2022-09-20 | 上海交通大学医学院附属新华医院 | GOLM1在制备负性调控cell-in-cell结构的形成的药物中的应用 |
| WO2022125504A1 (en) * | 2020-12-07 | 2022-06-16 | Iogenetics, Llc | Bystander protein vaccines |
| PE20250846A1 (es) | 2020-12-31 | 2025-03-21 | Immatics Us Inc | Polipeptidos cd8, composiciones y metodos de uso de estos |
| BR112023022975A2 (pt) | 2021-05-05 | 2024-01-23 | Immatics Biotechnologies Gmbh | Polipeptídeos de ligação ao antígeno bma031 melhorados |
| CN113350507B (zh) * | 2021-07-19 | 2022-04-15 | 南通大学 | Cep55作为靶点在制备诊断、预防或治疗结肠炎的药物中的应用 |
| JP2024534825A (ja) | 2021-08-24 | 2024-09-26 | イマティクス ユーエス，アイエヌシー． | 条件付きリガンド交換により産生されたペプチドｍｈｃ複合体を使用する免疫細胞の選択 |
| WO2023044488A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| EP4408468A4 (en) | 2021-09-28 | 2025-07-02 | Frontaim Biomedicines Inc | MULTIPLE FORMATS OF MOLECULAR COMPLEXES |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| CN114395625B (zh) * | 2021-12-29 | 2023-08-04 | 广东省人民医院 | Copa在制备子宫颈癌诊断生物标记物和/或子宫颈癌药物开发中的应用 |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| IL316515A (en) | 2022-04-28 | 2024-12-01 | Immatics Us Inc | Membrane-bound IL15 CD8 proteins, cells, compositions and methods for their use |
| EP4514821A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| CN114592006A (zh) * | 2022-04-29 | 2022-06-07 | 昆明理工大学 | Memo1基因的新用途 |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| CN114751961B (zh) * | 2022-06-14 | 2022-09-20 | 中山大学孙逸仙纪念医院 | circ0005199-173aa蛋白及其在制备食管癌诊断产品中的应用 |
| KR102921994B1 (ko) * | 2022-09-22 | 2026-02-03 | 차의과학대학교 산학협력단 | 파클리탁셀에 대하여 내성을 갖는 난소암의 진단을 위한 분석방법 |
| CN117074541B (zh) * | 2022-09-23 | 2025-11-25 | 西湖大学 | 预测卵巢癌病人辅助化疗敏感性的蛋白标志物及应用 |
| CN116042825B (zh) * | 2022-09-28 | 2025-07-01 | 南方医科大学 | 一种评估5-fu治疗胃癌癌敏感性的探针引物组及其试剂盒 |
| CN116064806B (zh) * | 2022-10-19 | 2023-09-22 | 常州国药医学检验实验室有限公司 | 一种评估早期胃癌淋巴结转移风险的组合物及其用途 |
| WO2025058100A1 (ko) * | 2023-09-12 | 2025-03-20 | (주)수파드엘릭사 | 레티노산 수용체 활성화 펩타이드 및 이를 포함하는 화장료 조성물 |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2026096743A1 (en) | 2024-10-30 | 2026-05-07 | Immatics US, Inc. | Methods for gamma delta t cells manufacturing |
| CN119287020B (zh) * | 2024-12-11 | 2025-03-07 | 湖南宏雅基因技术有限公司 | 一种甲状腺癌甲基化水平检测的引物探针组合物及其应用 |
| CN120966999B (zh) * | 2025-10-22 | 2026-01-09 | 宁波大学 | Klhl14基因在制备结肠癌、5-fu耐受结肠癌诊断试剂中的应用 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| DK171727B1 (da) | 1978-12-22 | 1997-04-14 | Biogen Inc | Rekombinante hepatitis B virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenspecifikke polypeptider, DNA-sekvenser kodende for HBV-antigenspecifikke polypeptider, metoder til påvisning af hepatitis B virus-antistoffer, metoder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider og midler til påvisning af HBV-infektion |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| DE69420137T2 (de) | 1993-06-03 | 1999-12-23 | Therapeutic Antibodies, Inc. | Herstellung von antikörperfragmenten |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| CA2243235C (en) | 1996-01-17 | 2010-08-10 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| TW452771B (en) * | 1998-09-18 | 2001-09-01 | Sony Corp | Reproduction apparatus and reproduction method |
| US6858710B2 (en) * | 1998-12-17 | 2005-02-22 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| US20020119158A1 (en) | 1998-12-17 | 2002-08-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| CA2395926A1 (en) | 1999-12-28 | 2001-07-05 | Curagen Corporation | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| IL151860A0 (en) | 2000-03-27 | 2003-04-10 | Technion Res & Dev Foundation | Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| AU7524601A (en) | 2000-06-05 | 2001-12-17 | Sunol Molecular Corp | T cell receptor fusions and conjugates and methods of use thereof |
| WO2003020884A2 (en) * | 2001-08-14 | 2003-03-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Method for rapid generation of mature dendritic cells |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| EP1485075A4 (en) | 2002-02-20 | 2006-04-26 | Dyax Corp | MHC-PEPTIDE COMPLEX BINDING LIGANDS |
| DE10225144A1 (de) | 2002-05-29 | 2003-12-18 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| WO2003104429A2 (en) * | 2002-06-10 | 2003-12-18 | Idec Pharmaceuticals Corporation | Genes overexpressed by ovarian cancer and their use in developing novel therapeutics |
| CA2491017A1 (en) | 2002-07-03 | 2004-01-15 | Immunogen, Inc. | Antibodies to non-shed muc1 and muc16, and uses thereof |
| NZ539225A (en) | 2002-10-09 | 2006-09-29 | Avidex Ltd | Single chain recombinant T cell receptors |
| AU2003276403B2 (en) | 2002-11-09 | 2010-04-15 | Adaptimmune Limited | T cell receptor display |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| US7348007B2 (en) * | 2004-02-09 | 2008-03-25 | Ludwig Institute For Cancer Research | Mage C2 antigenic peptides and uses thereof |
| DE102004026135A1 (de) | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| WO2006029176A2 (en) * | 2004-09-08 | 2006-03-16 | Ludwig Institute For Cancer Research | Cancer-testis antigens |
| JP4987698B2 (ja) | 2005-03-31 | 2012-07-25 | 中外製薬株式会社 | 癌関連抗原アナログペプチド、およびその利用 |
| JP4962687B2 (ja) | 2005-08-30 | 2012-06-27 | Ｎｏｋ株式会社 | 密封構造 |
| EP1806358B1 (en) | 2005-09-05 | 2010-03-17 | Immatics Biotechnologies GmbH | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
| EP1760089B1 (en) | 2005-09-05 | 2009-08-19 | Immatics Biotechnologies GmbH | Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine |
| JP5564249B2 (ja) | 2006-06-23 | 2014-07-30 | アレシア・バイオセラピューティクス・インコーポレーテッド | 癌に関与するポリヌクレオチド配列およびポリペプチド配列 |
| WO2008127285A2 (en) * | 2006-10-05 | 2008-10-23 | The Board Of Trustees Of The University Of Arkansas | Target peptides for ovarian cancer immunotherapy |
| AU2007350900A1 (en) | 2007-04-05 | 2008-10-16 | Source Precision Medicine, Inc. | Gene expression profiling for identification, monitoring and treatment of ovarian cancer |
| DK2183361T3 (en) | 2007-07-27 | 2015-07-27 | Immatics Biotechnologies Gmbh | Novel immunotherapy against brain tumors |
| BRPI0813626A2 (pt) * | 2007-07-27 | 2014-12-23 | Immatics Biotechnologies Gmbh | Epitopos imunogênicos para a imunoterapia |
| BRPI0814140A2 (pt) * | 2007-07-27 | 2017-03-28 | Immatics Biotechnologies Gmbh | composição de peptídeos associados a tumor e vacina anticâncer relacionada |
| WO2009067546A2 (en) | 2007-11-19 | 2009-05-28 | Celera Corpration | Lung cancer markers and uses thereof |
| US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
| US20100029748A1 (en) | 2008-08-04 | 2010-02-04 | Sloan-Kettering Institute For Cancer Research | Metastasis Promoting Genes and Proteins |
| RS53782B1 (sr) | 2008-10-01 | 2015-06-30 | Immatics Biotechnologies Gmbh | Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera |
| WO2010088688A2 (en) | 2009-02-02 | 2010-08-05 | Biotheranostics, Inc. | Diagnosis of in situ and invasive breast cancer |
| CN102348979A (zh) | 2009-03-09 | 2012-02-08 | 乔治亚大学研究基金公司 | 胃癌诊断用蛋白标记的鉴定 |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| WO2013040142A2 (en) * | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| US9169328B2 (en) | 2010-03-26 | 2015-10-27 | Memorial Sloan Kettering Cancer Center | Antibodies to MUC16 and methods of use thereof |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| CN103038635B (zh) | 2010-05-11 | 2016-12-28 | 威拉赛特公司 | 用于诊断病状的方法和组合物 |
| GB201009222D0 (en) | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| CN102372773B (zh) | 2010-08-11 | 2013-06-05 | 中国科学院生物物理研究所 | 人膀胱癌肿瘤标志物及其抗体和应用 |
| WO2012056407A1 (en) | 2010-10-26 | 2012-05-03 | Technion Research & Development Foundation Ltd. | Antibodies which bind soluble t-cell receptor ligands |
| SG10201604497UA (en) | 2011-06-02 | 2016-07-28 | Almac Diagnostics Ltd | Molecular Diagnostic Test For Cancer |
| JP2014526032A (ja) | 2011-06-07 | 2014-10-02 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． | 癌に対する循環バイオマーカー |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| US10208086B2 (en) | 2011-11-11 | 2019-02-19 | Fred Hutchinson Cancer Research Center | Cyclin A1-targeted T-cell immunotherapy for cancer |
| GB201201511D0 (en) * | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
| WO2014011465A2 (en) * | 2012-07-13 | 2014-01-16 | Albert Einstein College Of Medicine Of Yeshiva University | Aptamer-targeted antigen delivery |
| WO2014041185A2 (en) | 2012-09-17 | 2014-03-20 | Ait Austrian Institute Of Technology Gmbh | Colon cancer diagnostic method and means |
| EP2917388B1 (en) | 2012-11-08 | 2016-10-05 | Roche Diagnostics GmbH | Nucleic acids encoding chimeric polypeptides for library screening |
| EP2808392A1 (en) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |
| TWI777194B (zh) | 2013-08-05 | 2022-09-11 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（一） |
| SMT202000307T1 (it) * | 2014-05-28 | 2020-07-08 | Nono Inc | Sale cloruro di tat-nr2b9c |
| AU2015358387B2 (en) * | 2014-12-03 | 2019-07-25 | Verik Bio, Inc. | Identification, selection and use of high curative potential T cell epitopes |
| GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
-
2015
- 2015-07-01 GB GBGB1511546.2A patent/GB201511546D0/en not_active Ceased
-
2016
- 2016-06-29 SG SG10202001665QA patent/SG10202001665QA/en unknown
- 2016-06-29 MA MA41520A patent/MA41520B2/fr unknown
- 2016-06-29 RS RS20201506A patent/RS61190B1/sr unknown
- 2016-06-29 DK DK16733523.1T patent/DK3317296T3/da active
- 2016-06-29 MD MDE20180477T patent/MD3317296T2/ro not_active IP Right Cessation
- 2016-06-29 JP JP2017563564A patent/JP2018521641A/ja active Pending
- 2016-06-29 LT LTEP16733523.1T patent/LT3317296T/lt unknown
- 2016-06-29 UA UAA201711177A patent/UA123699C2/uk unknown
- 2016-06-29 WO PCT/EP2016/065166 patent/WO2017001491A2/en not_active Ceased
- 2016-06-29 EP EP16733523.1A patent/EP3317296B1/en active Active
- 2016-06-29 CN CN202110807868.2A patent/CN113480604A/zh active Pending
- 2016-06-29 SI SI201630998T patent/SI3317296T1/sl unknown
- 2016-06-29 EA EA201992664A patent/EA201992664A3/ru unknown
- 2016-06-29 AU AU2016286274A patent/AU2016286274B2/en not_active Ceased
- 2016-06-29 HU HUE16733523A patent/HUE052820T2/hu unknown
- 2016-06-29 MX MX2017017145A patent/MX2017017145A/es unknown
- 2016-06-29 EP EP20170129.9A patent/EP3712165A3/en not_active Withdrawn
- 2016-06-29 KR KR1020187003095A patent/KR20180022968A/ko not_active Ceased
- 2016-06-29 CR CR20180001A patent/CR20180001A/es unknown
- 2016-06-29 PT PT167335231T patent/PT3317296T/pt unknown
- 2016-06-29 CA CA2990989A patent/CA2990989A1/en active Pending
- 2016-06-29 BR BR112017027459-0A patent/BR112017027459A2/en not_active Application Discontinuation
- 2016-06-29 EA EA201792632A patent/EA201792632A1/ru unknown
- 2016-06-29 ES ES16733523T patent/ES2839223T3/es active Active
- 2016-06-29 MA MA050925A patent/MA50925A/fr unknown
- 2016-06-30 US US15/199,338 patent/US10738094B2/en active Active
- 2016-06-30 US US15/198,540 patent/US10047131B2/en active Active
- 2016-06-30 US US15/199,182 patent/US10227388B2/en active Active
- 2016-06-30 US US15/198,608 patent/US20170037111A1/en not_active Abandoned
- 2016-06-30 US US15/199,199 patent/US9908922B2/en not_active Expired - Fee Related
- 2016-06-30 US US15/199,244 patent/US10464978B2/en active Active
- 2016-06-30 US US15/199,270 patent/US10472401B2/en active Active
- 2016-06-30 US US15/198,853 patent/US10280205B2/en active Active
- 2016-06-30 US US15/199,066 patent/US10253076B2/en active Active
- 2016-06-30 US US15/198,471 patent/US10000539B2/en active Active
- 2016-06-30 US US15/198,620 patent/US20170002055A1/en not_active Abandoned
-
2017
- 2017-11-16 US US15/815,644 patent/US20180066032A1/en not_active Abandoned
-
2018
- 2018-05-15 US US15/980,328 patent/US10174089B2/en active Active
- 2018-08-10 US US16/101,081 patent/US10239925B2/en active Active
- 2018-12-06 US US16/212,178 patent/US10494413B2/en active Active
-
2019
- 2019-02-21 US US16/281,790 patent/US10533041B2/en active Active
- 2019-12-13 US US16/713,157 patent/US11485765B2/en active Active
-
2020
- 2020-06-29 US US16/915,745 patent/US10934333B2/en not_active Expired - Fee Related
-
2021
- 2021-01-29 AU AU2021200599A patent/AU2021200599B2/en not_active Ceased
- 2021-05-07 US US17/314,629 patent/US11912748B2/en active Active
- 2021-06-01 JP JP2021092252A patent/JP7404306B2/ja active Active